Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Asia Medical and Agricultural Laboratory and Research Center Public Company Limited (AMARC.BK)
Bangkok, TH
Asia Medical and Agricultural Laboratory and Research Center Public Company Limited (AMARC), established in Bangkok, Thailand, in 2004, offers a broad spectrum of laboratory services, focusing primarily on the agricultural, food, and pharmaceutical sectors. This subsidiary of Ladprao General Hospital Public Company Limited provides vital support across several key areas. The company delivers extensive testing, inspection, and certification for a diverse range of products, including meat and meat products, fats, oils, pet food, feedstuffs, aquaculture items, crops, and various other food and beverage commodities. They also perform environmental analyses on water, air, and soil samples, as well as potable water and water ice. For the agricultural industry, AMARC specializes in quality control and registration for fertilizers, in addition to conducting efficacy and residue trials and providing registration assistance for hazardous substances and pesticides. In the pharmaceutical realm, their services encompass quality assurance testing, research and development for drugs and raw materials, analysis of product components, drug analysis method validation, and bioequivalence studies. They also support the cosmetics industry with quality assurance, including contaminant and challenge tests, and are involved in developing new testing methodologies for pharmaceutical products. Beyond analytical testing, AMARC offers calibration services for electrical, temperature, chemical, and mechanical metrology, alongside calibrating various medical devices such as electrocardiograms, non-invasive blood pressure devices, patient monitors, and pulse oximeters. Additionally, the company provides expert consultation and training, guiding clients through quality system preparation (including ISO/IEC 17025 standards), inspection, and certification processes, as well as optimizing laboratory tools and equipment. Further services include nutrition labeling, shelf-life assessments, and analysis of food contact materials.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.06% | -9.33% | -5.91% | +1.16% | +29.63% | +34.62% | +102.31% | +52.17% | +20.69% | +20.69% | +20.69% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Hardware, Equipment & Parts: +10.0%+42.2% ★ Q1'26: +2.0% (vs Q1'25)
-
EPS growth Hardware, Equipment & Parts: +20.2%+300.0% ★ Q1'26: -2.9% (vs Q1'25)
-
FCF margin FCF growth · Hardware, Equipment & Parts: +27.1%+33.2% ★ Q1'26: +14.4% (vs Q1'25)
-
EBIT margin Hardware, Equipment & Parts: +8.7%+31.5% ★ Q1'26: +20.8% (vs Q1'25)
-
ROIC Hardware, Equipment & Parts: +5.7%+28.8% ★ Q1'26: +19.0% (vs Q1'25)
-
Share dilution Hardware, Equipment & Parts: +0.0%+0.0% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Hardware, Equipment & Parts: -0.70×0.15× Q1'26: 0.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
345.28M
est: 346.00M (-0.2%)
|
491.01M
est: 482.00M (+1.9%)
|
525.00M
525.00M – 525.00M
+8.9% YoY
|
550.00M
550.00M – 550.00M
+4.8% YoY
|
574.00M
574.00M – 574.00M
+4.4% YoY
|
| EBITDA |
81.73M
est: 89.56M (-8.8%)
|
196.13M
est: 124.77M (+57.2%)
|
135.90M
135.90M – 135.90M
+8.9% YoY
|
142.37M
142.37M – 142.37M
+4.8% YoY
|
148.58M
148.58M – 148.58M
+4.4% YoY
|
| EBIT |
41.38M
est: 49.79M (-16.9%)
|
154.62M
est: 69.36M (+122.9%)
|
75.55M
75.55M – 75.55M
+8.9% YoY
|
79.15M
79.15M – 79.15M
+4.8% YoY
|
82.60M
82.60M – 82.60M
+4.4% YoY
|
| Net Income |
39.90M
est: 37.80M (+5.6%)
|
158.56M
est: 144.48M (+9.7%)
|
162.12M
162.12M – 162.12M
+12.2% YoY
|
163.80M
163.80M – 163.80M
+1.0% YoY
|
168.00M
168.00M – 168.00M
+2.6% YoY
|
| SGA |
102.23M
est: 100.36M (+1.9%)
|
110.67M
est: 139.80M (-20.8%)
|
152.27M
152.27M – 152.27M
+8.9% YoY
|
159.52M
159.52M – 159.52M
+4.8% YoY
|
166.49M
166.49M – 166.49M
+4.4% YoY
|
| EPS |
0.10
est: 0.09 (+5.6%)
|
0.38
est: 0.34 (+10.5%)
|
0.39
0.39 – 0.39
+12.2% YoY
|
0.39
0.39 – 0.39
+1.0% YoY
|
0.40
0.40 – 0.40
+2.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | S- | 5/5 | 4/5 | 5/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-21 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-20 | S- | 5/5 | 4/5 | 5/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-18 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-15 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-14 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-13 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-12 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-11 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-08 | A+ | 5/5 | 4/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-23 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-22 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-21 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-20 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-17 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-16 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMARC.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
